Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study

Cinzia Aurilia; Sabina Cevoli; Gabriella Egeo; Luisa Fofi; Roberta Messina; Antonio Salerno; Paola Torelli; Maria Albanese; Antonio Carnevale; Francesco Bono; Domenico D’Amico; Massimo Filippi; Claudia Altamura; Fabrizio Vernieri; Bruno Colombo; Fabio Frediani; B. Mercuri; Florindo d’Onofrio; Licia Grazzi; Marco Aguggia; Valentina Favoni; Cinzia Finocchi; Paola Di Fiore; Carlemina Maria Costa; Nicoletta Brunelli; Adriana Fallacara; Davide Bertuzzo; Maurizio Zucco; Laura Di Clemente; Michele Trimboli; Angelo Pascarella; Lucia Manzo; Piero Barbanti

doi:10.1016/j.jns.2021.117716

Related publications

Article2021

Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Piero Barbanti, Cinzia Aurilia, Sabina Cevoli, Gabriella Egeo, Luisa Fofi, Roberta Messina, Antonio Salerno, Paola Torelli, Maria Albanese, Antonio Carnevale, Francesco Bono, Domenico D’Amico, Massimo Filippi, Claudia Altamura, Fabrizio Vernieri

Article2021

Long-term (>48 weeks) safety and tolerability of erenumab in real-life

Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Sabina Cevoli, Roberta Messina, Antonio Salerno, Paola Torelli, Maria Albanese, Antonio Carnevale, Francesco Bono, Domenico D’Amico, Massimo Filippi, Claudia Altamura, Fabrizio Vernieri, Bruno Colombo, Fabio Frediani, B. Mercuri, Florindo d’Onofrio, Licia Grazzi, Marco Aguggia, Valentina Favoni, Cinzia Finocchi, Paola Di Fiore, Carlemina Maria Costa,

Article2020

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Sabina Cevoli, Bruno Colombo, Massimo Filippi, Fabio Frediani, Francesco Bono, Licia Grazzi, Antonio Salerno, B. Mercuri, Antonio Carnevale, Claudia Altamura, Fabrizio Vernieri

Article2020

The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine (2307)

Piero Barbanti, Cinzia Aurilia, Sabina Cevoli, Bruno Colombo, Fabio Frediani, Francesco Bono, Licia Grazzi, Domenico D’Amico, Antonio Salerno, B. Mercuri, Antonio Carnevale, Catello Vollono, Gabriella Egeo, Luisa Fofi, Claudia Altamura, Cármen Costa, Nicoletta Brunelli, Adriana Fallacara, Giulia Pierangeli, Valentina Favoni, Roberta Messina, Massimo Filippi, ,

Article2024

Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study

Piero Barbanti, Bianca Orlando, Gabriella Egeo, Florindo d’Onofrio, Alberto Doretti, Stefano Messina, Massimo Autunno, Roberta Messina, Massimo Filippi, Giulia Fiorentini, Cristina Rotondi, Stefano Bonassi, Cinzia Aurilia